Imbio PHA (4.0.0) vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Both tools leverage AI for cardiac diagnostics, but they target different conditions and utilize distinct imaging modalities. Imbio PHA analyzes CT pulmonary angiogram (CTPA) scans to assess right ventricular dilation for pulmonary embolism and hypertension, whereas Ultromics' EchoGo Amyloidosis screens echocardiogram video clips for the early detection of cardiac amyloidosis.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Imbio PHA (4.0.0) is designed to assess potential right ventricular dilation from CT pulmonary angiogram (CTPA) scans, aiding in the diagnosis and risk stratification of pulmonary embolism and hypertension. EchoGo Amyloidosis is an FDA-cleared AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis.
Imbio PHA (4.0.0) specifically utilizes CT pulmonary angiogram (CTPA) scans for its analysis. EchoGo Amyloidosis analyzes echocardiogram video clips to identify suspected cardiac amyloidosis.
EchoGo Amyloidosis has specific reimbursement codes: NTAP Code ICD-10 XXE2X19 for inpatient analysis ($1,000) and HCPCS Code C9786 (Clinical APC Code 574) for outpatient analysis ($285). These are covered by Medicare and select commercial insurers. Imbio PHA (4.0.0) requires contacting the company for pricing details.
Imbio PHA (4.0.0) provides automated measurements of right and left ventricle diameters, main pulmonary artery and aorta diameters, calculates RV/LV and PA/Ao ratios, and generates annotated DICOM images and summary PDF reports. EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis, based on its analysis of echocardiographic markers.
EchoGo Amyloidosis reports high diagnostic accuracy with 85% sensitivity and 93% specificity for identifying suspected cardiac amyloidosis, with consistent performance across AL, wild-type ATTR, and variant ATTR subtypes. Imbio PHA (4.0.0) has demonstrated accuracy in measuring RV/LV and PA/Ao ratios when compared with expert radiologists.
Imbio PHA (4.0.0) is intended for Cardiology, Pulmonology, and Radiology specialties. EchoGo Amyloidosis is specifically designed to support Cardiology.